Dose- and Time-Related Effects of Pilocarpine Mouthwash on Salivation

다국어 초록 (Multilingual Abstract)

Purpose: Pilocarpine as a salivation stimulant in pill form has mostly been used to relieve oral dryness for xerostomic patients but its use may often be limited due to variable side effects from systemic absorption. Therefore, the purpose of this study was to investigate the effects of pilocarpine mouthwash on salivation according to the variable concentration and duration for healthy volunteers. Related adverse effects and subjective assessment on its effects on salivation were also examined.
Methods: This study was performed as placebo-controlled, double-blind, randomized clinical trial. Thirty healthy volunteers (male=23, mean age=22.2 years) were randomly allocated to 6 groups with the different concentration of pilocarpine mouthwash (placebo, 0.1%, 0.5%, 1.0%, 1.5%, and 2.0%). The whole experiment consisted of 3 sessions according to the duration of mouthwash, i.e., 1, 3, and 5 minutes with the mean wash-out period ≥2 days between the sessions. Unstimulated whole saliva was collected before and after gargling with a mouthwash.
Results: Salivation of the higher concentration groups ≥1% significantly increased than those of lower concentration group. The application period of mouthwash did not cause any changes of salivary flow rate at the higher concentrations ≥1.0%. The lower concentrations of 0.5% and 0.1% had no effects on salivation even after 5-minute mouthwash. There was no significant difference between blood pressure and pulse rate before and after use of mouthwash.
Conclusions: From the results of the current study, pilocarpine mouthwash with at least 1.0% concentration more than a minute might be clinically effective in salivation without any serious side effects. Dose of mouthwash rather than duration seems to be a critical factor to salivation.

참고문헌 (Reference)

1 Hopcraft MS, "Xerostomia: an update for clinicians" 55 : 238-244, 2010

2 Rosas J, "Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren’s syndrome. Correlation with clinical, immunological and histological features" 41 : 670-675, 2002

3 Schuller DE, "Treatment of radiation side effects with oral pilocarpine" 42 : 272-276, 1989

4 Collins LM, "The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa" 66 : 1300-1302, 1987

5 Berk L, "Systemic pilocarpine for treatment of xerostomia" 4 : 1333-1340, 2008

6 Fox PC, "Subjective reports of xerostomia and objective measures of salivary gland performance" 115 : 581-584, 1987

7 Mandel ID, "Sialochemistry in diseases and clinical situations affecting salivary glands" 12 : 321-366, 1980

8 Weaver ML, "Salivary flow induction by buccal permucosal pilocarpine in anesthetized beagle dogs" 71 : 1762-1767, 1992

9 Orellana MF, "Prevalence of xerostomia in population-based samples: a systematic review" 66 : 152-158, 2006

10 Lockhart PB, "Pilot study of controlled-release pilocarpine in normal subjects" 82 : 517-524, 1996

11 Fox PC, "Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia)" 151 : 1149-1152, 1991

12 Mikhail AR, "Pilocarpine mouthwash for dry mouth relief"

13 Wiseman LR, "Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia" 49 : 143-155, 1995

14 Johnson JT, "Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer" 329 : 390-395, 1993

15 Ishii M, "Muscarinic acetylcholine receptors" 12 : 3573-3581, 2006

16 Fox PC, "Management of dry mouth" 41 : 863-875, 1997

17 Park KH, "Evaluations on salivary flow induction and dissolution patterns in saliva of pilocarpine chewing tablet in healthy human volunteers" 27 : 331-335, 1997

18 Taweechaisupapong S, "Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer" 51 : 333-337, 2006

19 Greenspan D, "Effectiveness of pilocarpine in postradiation xerostomia" 59 : 1123-1125, 1987

20 Bernardi R, "Effect of pilocarpine mouthwash on salivary flow" 35 : 105-110, 2002

21 Hamlar DD, "Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma" 106 : 972-976, 1996

22 Park JE, "Comparison of pilocarpine solution and tablet on salivary flow rate" Dankook University 2012

23 Porter SR, "An update of the etiology and management of xerostomia" 97 : 28-46, 2004

24 Frydrych AM, "An investigation into the use of pilocarpine as a sialagogue in patients with radiation induced xerostomia" 47 : 249-253, 2002

25 LeVeque FG, "A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients" 11 : 1124-1131, 1993